News

Histone variant may contribute to lymphoma


 

DNA coiled around histones

Image by Eric Smith

Researchers say they have identified histone chaperones that play an important role in the structure of chromatin.

The team believes this finding, published in Molecular Cell, could lead to a better understanding of lymphomas and other cancers.

“Maintaining an appropriate chromatin structure is essential for normal development, and, not surprisingly, defects in chromatin components can lead to several diseases,” said study author François Robert, PhD, of Institut de Recherches Cliniques de Montréal in Québec, Canada.

In studying chromatin, Dr Robert and his colleagues have been interested in a histone variant called H2A.Z.

The researchers knew that H2A.Z is incorporated into promoter regions of the gene by SWR-C-related chromatin remodeling complexes, but they wanted to determine if H2A.Z is actively excluded from non-promoter regions.

“With this study, we discovered that 2 other proteins, FACT and Spt6, play an important role in the location of H2A.Z,” said Célia Jeronimo, PhD, a research associate in Dr Robert’s lab.

The team found that FACT and SPt6 both help keep H2A.Z from accumulating in intragenic regions. When either histone chaperone is absent, H2A.Z is mislocalized, which alters chromatin composition and contributes to cryptic transcription.

“Inappropriate H2A.Z localization has previously been observed in cancer cells, but little was understood about the consequences of this phenomenon,” Dr Robert said.

“Although our study was performed in yeast cells, it suggests that mislocalization of H2A.Z may lead to cryptic transcription in some types of cancer such as lymphoma, and this may contribute to the disease. Our next step is therefore to investigate the possible role of H2A.Z and its associated gene expression defects in cancer cells.”

Recommended Reading

Dexrazoxane Tx did not affect overall survival in pediatric leukemia and lymphoma
MDedge Hematology and Oncology
CHMP recommends drug for WM
MDedge Hematology and Oncology
Herbs reduce fatigue in cancer patients
MDedge Hematology and Oncology
Team reports new method to identify immune cells
MDedge Hematology and Oncology
CTLs captured on video destroying cancer cells
MDedge Hematology and Oncology
How mAbs produce lasting antitumor effects
MDedge Hematology and Oncology
Combo targets AML, BL in the same way
MDedge Hematology and Oncology
Company stops phase 3 PTCL trial
MDedge Hematology and Oncology
Familial factors linked to child’s risk of blood cancer
MDedge Hematology and Oncology
Inhibitor promotes chemosensitization in CLL
MDedge Hematology and Oncology